Abstract
“If it were not for the great variability among individuals medicine might as well be a science and not an art.” The thoughts of Sir William Osler in 1892 reflect the view of medicine over the past 100 years. The role of physicians in making the necessary judgements about the medicines that they prescribe is often referred to as an art, reflecting the lack of objective data available to make decisions that are tailored to individual patients. Just over a hundred years later we are on the verge of being able to identify inherited differences between individuals which can predict each patient's response to a medicine. This ability will have far-reaching benefits in the discovery, development and delivery of medicines. Sir William Osler, if he were alive today, would be re-considering his view of medicine as an art not a science.
This is a preview of subscription content, access via your institution
Access options
Subscribe to this journal
Receive 51 print issues and online access
$199.00 per year
only $3.90 per issue
Buy this article
- Purchase on Springer Link
- Instant access to full article PDF
Prices may be subject to local taxes which are calculated during checkout
Similar content being viewed by others
References
Curran, M. E. Potassium ion channels and human disease: phenotypes to drug targets? Curr. Opin. Biotechnol. 9, 565–572 (1998).
Marton, M. J. et al. Drug target validation and identification of secondary drug target effects using DNA microarrays. Nature Med. 4 , 1293–1301 (1998).
Wiley, S. R. Genomics in the real world. Curr. Pharmaceut. Des. 4, 417–422 (1998).
Blackstock, W. P. & Weir, M. P. Proteomics: quantitative and physical mapping of cellular proteins. Trends Biotechnol. 17, 121–127 (1999).
Kozian, D. H. & Kirschbaum, B. J. Comparative gene-expression analysis. Trends Biotechnol. 17, 73– 78 (1999).
Rockett, J. C., Esdaile, D. J. & Gibson, G. G. Differential gene expression in drug metabolism and toxicology: practicalities, problems and potential. Xenobiotica 29, 655–691 ( 1999).
Roses, A. D. Apolipoprotein E affects the rate of Alzheimer disease expression: beta-amyloid burden is a secondary consequence dependent on APOE genotype and duration of disease. J. Neuropathol. Exp. Neurol. 53, 429–437 (1994).
Saunders, A. M. Apolipoprotein E and Alzheimer's disease: an update on genetic and functional analyses. J. Neuropathol. Exp. Neurol. (in the press).
Boschert, U., Merlo-Pich, E., Higgins, G., Roses, A. D. & Catsicas, S. Apolipoprotein E expression by neurons surviving excitotoxic stress. Neurobiol. Dis. 6, 508–514 (1999).
Xu, P. T. et al. Human apolipoprotein E2, E3 and E4 isoform-specific transgenic mice: human-like pattern of neuronal immunoreactivity in central nervous system not observed in wild type mice. Neurobiol. Dis. 3, 229–245 (1996).
Xu, P. T. et al. Regionally specific neuronal expression of human APOE gene in transgenic mice. Neurosci. Lett. 246, 65 –68 (1998).
Xu, P. T. et al. Specific regional transcription of apolipoprotein E in human brain neurons. Am. J. Pathol. 154, 601– 611 (1999).
Huang, J. T. et al. Interleukin-4-dependent production of PPAR-γ ligands in macrophages by 12/15-lipoxygenase. Nature 400, 378–382 (1999).
Kliewer, S. A. Lehmann, J. M. & Wilson, T. M. Orphan nuclear receptors: shifting endocrinology into reverse. Science 284, 757– 760 (1999).
Barroso, I. et al. Dominant negative mutations in human PPARγ associated with severe insulin resistance, diabetes mellitus and hypertension. Nature 402, 880–883 ( 1999).
Roses, A. D. Apolipoprotein E alleles as risk factors in Alzheimer's disease. Annu. Rev. Med. 47, 387–400 (1996).
Goate, A. et al. Segregation of a missense mutation in the amyloid precursor protein gene with familial Alzheimer's disease. Nature 349, 704–706 (1991).
Levy-Lehad, E. et al. Candidate gene for the chromosome 1 familial Alzheimer's disease locus. Science 269, 973– 977 (1995).
Sherrington, R. et al. Cloning of a gene bearing missense mutations in early-onset familial Alzheimer's disease. Nature 375, 754–760 (1995).
Van Nostrand, W. E., Wagner, S. L., Haan, J., Bakker, E. & Roos, R. A. Alzheimer's disease and hereditary cerebral hemorrhage with amyloidosis-Dutch type share a decrease in cerebrospinal fluid levels of amyloid beta-protein precursor. Ann. Neurol. 32, 215–218 (1992).
Aitman, T. J. & Todd, J. A. Molecular genetics of diabetes mellitus . Baillieres Clin. Endocrinol. Metabol. 9, 631–656 (1995).
Sandford, A., Weir, T. & Pare, P. The genetics of asthma. . Am. J. Respir. Crit. Care Med. 153, 1749–1765 (1996).
Schork, N. J. Genetics of complex disease: approaches, problems, and solutions. Am. J. Respir. Crit. Care Med. 156, S103– S109 (1997).
Concannon, P. et al. A second-generation screen of the human genome for susceptibility to insulin-dependent diabetes mellitus. Nature Genet. 19, 292–296 (1998).
Howard, T. D. et al. Genetics of allergy and bronchial hyperresponsiveness. Clin. Exp. Allergy 29(Suppl.), 86– 89 (1999).
Talley, N. J. Irritable bowel syndrome: disease definition and symptom description. Eur. J. Surg. 583(Suppl.), 24– 28 (1998).
Paterson, W. G. et al. Recommendations for the management of irritable bowel syndrome in family practice. IBS Consensus Conference Participants. Can. Med. Assoc. J. 161, 154–160 (1999).
Hamm, L. R. et al. Additional investigations fail to alter the diagnosis of irritable bowel syndrome in subjects fulfilling the Rome criteria. Am. J. Gastroenterol. 94, 1279–1282 (1999).
Evans W. E. & Relling, M. V. Pharmacogenomics: translating functional genomics into rational therapeutics. Science 286, 487–491 (1999).
Meyer, U. A. & Zanger, U. M. Molecular mechanisms of genetic polymorphisms of drug metabolism. Annu. Rev. Pharmacol. Toxicol. 37, 269–296 ( 1997).
Cohen, L. J. & DeVane, C. L. Clinical Implications of antidepressant pharmacokinetics and pharmacogenetics. Ann. Pharmacotherapy 3, 1471–1480 (1996).
Rudorfer, M. V., Lane, E. A., Chang, W. H., Zhang, M. & Potter, W. Z. Desipramine pharmacokinetics in Chinese and Caucasian volunteers. Br. J. Clin. Pharmacol. 17, 433–440 (1984).
Mueller, R. F. & Young, I. D. in Emery's Elements of Medical Genetics (ed. Kalow, W.) 169–175 (Churchill Livingstone, Edinburgh, 1997).
Zhao, L. P., Aragaki, C., Hsu, L. & Quiaoit, F. Mapping of complex traits by single-nucleotide polymorphisms. Am. J. Hum. Genet. 63, 225–240 (1998).
Brookes, A. J. The essence of SNPs. Gene 234, 177– 186 (1999).
Hacia, J. G. et al. Determination of ancestral alleles for human single-nucleotide polymorphisms using high-density oligonucleotide arrays. Nature Genet. 22, 164–167 ( 1999).
Marez, D. et al. Polymorphism of the cytochrome P450 CYP2D6 gene in a European population: characterization of 48 mutations and 53 alleles, their frequencies and evolution. Pharmacogenetics 7, 193– 202 (1997).
McKusick, V. A. Foreword to Mendelian Inheritance in Man 10th edn, vol. 1 , xv–xxxvii (The Johns Hopkins University Press, Baltimore, 1992).
Lai, E., Riley, J., Purvis, I. & Roses, A. A 4-Mb high-density single nucleotide polymorphism-based map around human APOE. Genomics 54, 31–38 ( 1998).
Martin, E. R. et al. Analysis of association at single nucleotide polymorphisms in the APOE region. Genomics 63, 7– 12 (2000).
Kruglyak, L. Prospects for whole-genome linkage disequilibrium mapping of common disease genes. Nature Genet. 22, 139– 144 (1999).
Collins, A., Lonjou, C. & Morton, N. E. Genetic epidemiology of single-nucleotide polymorphisms . Proc. Natl Acad. Sci. USA. 96, 15173– 15177 (1999).
Ott, J. Predicting the range of linkage disequilibrium. Proc. Natl Acad. Sci. USA. 97, 2–3 (2000 ).
Chen, J. et al. Microsphere-based assay for single-nucleotide polymorphism analysis using single base chain extension. Genome Res. 10, 549–557 (2000).
Roses, A. D., Manasco, P. & Freeman, A. J. Pharmacogenetics and genetics to discover new medicines . J. Comm. Biotech. (in the press).
Roses, A. D. Pharmacogenetics and the future of drug development and delivery. Lancet 355, 1358–1361 ( 2000).
Alon, U. et al. Broad patterns of gene expression revealed by clustering analysis of tumor and normal colon tissues probed by oligonucleotide arrays. Proc. Natl Acad. Sci. USA 96, 6745– 6750 (1999).
Bonnie, A., Fijal, M. S., Hall, J. M. & Witte, J. S. Clinical trials in the genomic era. Effects of protective genotypes on sample size and duration of trial 2000. Controlled Clin. Trials 21, 7–20 (2000).
Lazarou, J., Pomeranz, B. H. & Corey, P. N. Incidence of adverse drug reactions in hospitalized patients: a meta-analysis of prospective studies. J. Am. Med. Assoc. 279, 1200–1205 ( 1998).
Wood, A. J., Stein, C. M. & Woosley, R. Making medicines safer—the need for an independent drug safety board. N. Engl. J. Med. 339, 1851–1854 (1998).
White, J. Targets and systems of health care cost control. J. Health Politics Policy Law 24, 653–696 ( 1999).
Mather, D. B., Sullivan, S. D., Augustein, D., Fullerton, P. & Atherton, D. Incorporating clinical outcomes and economic consequences into drug formulary decision: a practical approach . Am. J. Man. Care 5, 277– 285 (1999).
McConnell, L. M. B. et al. Genetic testing and Alzheimer disease: recommendations of the Stanford Program in Genomics, Ethics, and Society. Genetic Testing 3, 3–12 ( 1999).
Koenig, B. A., Greely, H. T., McConnell, L. M., Silveberg, H. L. & Raffin, T. A. Genetic testing for BRCA1 and BRCA2: recommendations of the Stanford Program in Genomics, Ethics, and Society. Breast Cancer Working Group. J. Womens Health 7, 531–545 ( 1998).
Taningher, M., Malacarne, D., Izzotti, A., Ugolini, D. & Parodi, S. Drug metabolism polymorphisms as modulators of cancer susceptibility. Mutation Res. 436, 227–261 (1999).
Saunders, A. M. et al. Specificity, sensitivity, and predictive value of apolipoprotein-E genotyping for sporadic Alzheimer's disease. Lancet 348, 90–93 (1996).
Mayeux, R., et al. Utility of the apolipoprotein E genotype in the diagnosis of Alzheimer's disease. Alzheimer's disease Centers Consortium on Apolipoprotein E and Alzheimer's disease. N. Engl. J. Med. 338, 506–511 (1998). [Published erratum appears in N. Engl. J. Med. 338, 1325 (1998).]
Roses, A. D. Genetic testing for Alzheimer disease. Practical and ethical issues. Arch. Neurol. 54, 1226–1229 (1997).
Roses, A. D. Apolipoprotein E is a relevant susceptibility gene that affects the rate of expression of Alzheimer's disease. Neurobiol. Aging 15(Suppl 2), S165–S167 ( 1994).
Acknowledgements
I acknowledge my colleagues at Glaxo Wellcome in the development of the strategies outlined in this review; in particular, the vision and support of J. Niedel and the commitment of the Glaxo Wellcome R&D Executive Committee — A. Baxter, T. Eaves, A. Hennah and J. Palmer — in using their wealth of experience to help make this vision become a reality. I also thank the Genetics Directorate at Glaxo Wellcome for their expertise and continued hard work. Some of the recent pre-publication work carried out by Glaxo Wellcome scientists is reviewed in this paper. I especially thank A. Freeman, A. Saunders and A. Kidgell for expert editorial assistance.
Author information
Authors and Affiliations
Rights and permissions
About this article
Cite this article
Roses, A. Pharmacogenetics and the practice of medicine. Nature 405, 857–865 (2000). https://doi.org/10.1038/35015728
Issue Date:
DOI: https://doi.org/10.1038/35015728
This article is cited by
-
Pharmacogenetic profiling and individualised therapy in the treatment of degenerative spinal conditions
Irish Journal of Medical Science (1971 -) (2023)
-
Predictive genomic tools in disease stratification and targeted prevention: a recent update in personalized therapy advancements
EPMA Journal (2022)
-
X-change symposium: status and future of modern radiation oncology—from technology to biology
Radiation Oncology (2021)
-
A Decade of Pharmacogenetic Studies in Jordan: A Systemic Review
The Pharmacogenomics Journal (2021)
Comments
By submitting a comment you agree to abide by our Terms and Community Guidelines. If you find something abusive or that does not comply with our terms or guidelines please flag it as inappropriate.